

Fluid responsiveness Monitoring in Surgical and Critically III Patients



Impact clinique de la Goal-directed-therapy

Patrice FORGET, M.D.

Cliniques universitaires Saint Luc Université catholique de Louvain, Brussels, Belgium.



Introduction



- Expansion volémique
 - □Intervention fréquente et importante
 - □But: augmenter le *stroke volume* pour améliorer l'outcome
- Individualiser le remplissage reste un challenge
 - □ Prédire la réponse au remplissage
 - □Eviter l'hypo- comme l'hypervolémie



Why do I need to fill my patient?



- To rise his CO
- To improve clinical parameters
- To improve oxygen delivery
- To correct lactic acidosis
- **.** . . .

Rapidity is determinant!



But fluid loading may be insufficient




- Only 40 to 72% "responders"
- Cardiac failure, organic pathologies, renal tubulopathy

And potentially harmful...







Kehlet et al, BJA 2002



Fluids may be harmful!



- To fear hypo- as hypervolemia
- Liberal vs Restrictive?
 - □ Interest of the fluid restriction in major abdominal surgery but...
 - □ Debate still open
 - Holte et al, B J Anaesth 2007
 - □Tailoring the fluid management
 - Poeze et al, Crit Care 2005




Fluids may be harmful!



Optimization of perioperative fluid management may include a combination of limited crystalloid administration together with individualized goal-directed colloid administration to maintain a maximal stroke volume


Bungaard-Nielsen, Secher and Kehlet et al, Acta Anaesthesiol Scand 2009






Fluid volume





Fluid volume





Fluid volume






- To fill before the clinical signs of hypovolemia
 - □ To optimise the CO
 - □ To improve the morbi- mortality
 - To improve the quality of care and accelerate the rehabilitation
 - □ To shorten the hospital stay
 - □ To limit the costs






Goal directed therapy Well defined parameters Which parameters?









Preload





- Clinical signs and context
- Evolution of static "classical" parameters (CVP, PAOP, CF)
- Dynamic tests (Passive leg raising, fluid challenge)
- Biological parameters
 - □ Helpful but insufficient!






- Dynamic parameters
 - Cyclic variations of cardiac preload
 - □ Preload-dependency analysis
 - PPV (deltaPP), SVV, SPV, dDown, PVI

Pulse Pressure Variation





Michard et al, Am J Resp Crit C Med 2000.



Pulse Pressure Variation




Inspiratory positive pressure

- ↓ venous return
- ↓ right ventricular output
- ↓ left ventricular preload
- ↑ transmural pressures
- ↑ ANS








Boulain et al, Chest 2002





Michard et al, Am J Resp Crit C Med 2000.



Pulse Pressure Variation



- Colorectal (Haifang et al, Chin Med J 2002)
- Pheo (Mallat et al, C J Anesth 2003)
- CABG (Cannesson et al, A&A 2008)
- PO CABG (Rex et al, B J Anaesth 2004)
- Hepatectomy (Solus et al, B J Anaesth 2006)
- High-risk (Lopes et al, Crit Care 2007)



Dynamic parameters



Method	Advantages	Limitations
Minimally Invo	ısive	
ΔΡΡ	Considered gold standard for accuracy Clinical validation	Subject to con- founding effects



Dynamic parameters



Method	Advantages	Limitations
Invasive		
SVV, \triangle PP (PiCCO Plus; Pulsion Medical Systems AG)	Clinical validation SVV Pulse pressure variations Multimodal monitoring (eg, CO, vascular resistances)	Requires specific material Calibration No artifact detection Proprietary algorithm





Method	Advantages	Limitations
Minimally Invo	ısive	
SVV (FloTrac/	Multimodal monitoring (eg, CO, vascular resistances)	Requires specific material
Vigileo; Edwards Lifesciences	No calibration Clinical validation	No artifact detection
Lifesciences LLC)		Divergent data regarding cardiac output determination
		Proprietary algorithm





Method	Advantages	Limitations
Minimally Invo	ısive	
SVV (FloTrac/	Multimodal monitoring (eg, CO, vascular resistances)	Requires specific material
Vigileo; Edwards Lifesciences	No calibration Clinical validation	No artifact detection
Lifesciences LLC)		Divergent data regarding cardiac output determination
		Proprietary algorithm



Pulse Pressure Variation



- But...
 - □ Actually limited to controlled ventilation
 - ☐ In the absence of arrhythmia
 - Importance of the clinical context!
 - Orthopic liver transplantation (Gouvêa et al, B J Anaesth 2009)
 - □ In the case of automated calculation, importance of the validation of the software!
 - Vigileo? (Lahner et al, B J Anaesth 2009)
 - Dynamic invasive methods are often impractical, complex and costly.



Dynamic parameters




Method	Advantages	Limitations
Noninvasive		
PVI (part of Masimo Rainbow SET platform; Masimo Corp.)	Multimodal monitoring (eg, hemoglobin, oxygen content) No calibration Real-time and continuous information Ease of use Clinical validation	Vasomotor tone No artifact detection Proprietary algorithm



PPV and deltaPOP





Cannesson et al, Crit Care 2005.




deltaPOP and PVI



- Haifang et al, Chin Med J 2002
- Cannesson et al, Crit Care 2005
- Natalini et al, Anesthesiology 2006
- Solus et al, B J Anaesth 2006
- Cannesson et al, B J Anaesth 2008
 - □ PVI >14% predicts fluid responsiveness.


Pleth Variability Index





Pleth Variability Index





Adapted from Cannesson M et al. Br J Anaesth. 2008 Jun 2. [Epub ahead of print]

v

Pleth Variability Index

- 43 mechanically-ventilated septic shock patients
- 500 ml saline fluid challenge, passive leg raising
- Results
 - □ Correlation of 0.90 for PVI vs. ∆PP
 - □ PVI >20 vs. ΔPP >15%
 - Sensitivity 84%, specificity 90%
 - □ PVI >20 was 100% accurate in discriminating fluid responders from non-responders Feissel *et al.* ISICEM 2009.



Optimisation of the PVI?



- To guide fluid management and to optimise circulatory status during the surgery?
- Randomised Clinical Trial
 - □ to compare the intraoperative PVI-directed fluid management vs standard care
 - □ Clinicaltrials.gov Number NCT00816153





Group PVI (P)

- □ 500 mL of cristalloids followed by 2 mL.kg-1.h-1
- □ Colloids 250 mL added for a PVI value of 10 to 13%
- ☐ If required, vasoactive support to maintain the mean arterial pressure above 65 mmHg

Group Control (C)

 500 mL of cristalloids followed by fluid management based on fluid challenges and CVP


Forget P, Lois F and De Kock M, Anesth Analg 2010.





- Primary outcome
 - ☐ Perioperative lactate levels
- Secondary outcomes
 - ☐ Hemodynamic data
 - □ Postoperative complications





Forget P, Lois F and De Kock M, Anesth Analg 2010.



Table 1. Preoperative Characteristics, Incidence of Chronic Diseases, Type and Duration of Surgery and Anesthesia, Use of Epidural Analgesia in the Pleth Variability Index (PVI) Group (PVI-Guided Fluid Management) and Control Group

	PVI group (N = 41)	Control group $(N = 41)$
Age (years)	59 ± 14	61 ± 12
Weight (kg)	71 ± 15	68 ± 16
Height (cm)	169 ± 9	170 ± 9
Sex (female/male)	16/25 (39/61)	16/25 (39/61)
ASA score		
2	22 (54)	22 (54)
3	19 (46)	19 (46)
Chronic diseases		
Cirrhosis	3 (7)	0 (0)
Chronic obstructive pulmonary	2 (5)	2 (5)
disease		
Hypertension	18 (44)	13 (32)
Peripheral vascular disease	7 (17)	7 (17)
Coronary artery disease	5 (12)	2 (5)
Other cardiomyopathy	2 (5)	4 (10)
Diabetes mellitus	4 (10)	2 (5)

Forget P, Lois F and De Kock M, Anesth Analg 2010.



Table 1. Preoperative Characteristics, Incidence of Chronic Diseases, Type and Duration of Surgery and Anesthesia, Use of Epidural Analgesia in the Pleth Variability Index (PVI) Group (PVI-Guided Fluid Management) and Control Group

	PVI group (N = 41)	Control group (N = 41)
Preoperative biological values		
Hemoglobin (g \cdot dL ⁻¹)	12.5 ± 2	12.7 ± 2
Serum creatinine (mg ⋅ dL ⁻¹)	0.96 ± 0.2	0.97 ± 0.3
Type of surgery		
Upper gastrointestinal	7 (17)	5 (12)
Hepato-biliary	11 (27)	15 (37)
Lower gastrointestinal	24 (59)	22 (54)
Laparoscopic approach	5 (12)	5 (12)
Duration of surgery (minutes)	295 ± 125	301 ± 154
Duration of anesthesia	346 ± 125	356 ± 158
(minutes)		
Epidural analgesia	33 (81)	29 (71)

Forget P, Lois F and De Kock M, Anesth Analg 2010.





Table 2. Fluids Administered, Blood Loss, Hemodynamic Status, Physiologic Status, and Renal Function During and After Surgery in the Pleth Variability Index (PVI) Group (PVI-Guided Fluid Management) and in the Control Group

	PVI group (<i>N</i> = 41)	Control group (N = 41)	<i>P</i> value
Intraoperative fluids (mL)			
Crystalloids	1363 [1185–1540]	1815 [1568–2064]	0.004
Colloids	890 [709–1072]	1003 [779–1227]	0.43
Blood products	141 [53–230]	99 [20–179]	0.48
Total of intraoperative fluids	2394 [2097–2692]	2918 [2478–3358]	0.049
Blood losses	349 [230–468]	440 [242–637]	0.43
Postoperative fluids (24 hours)	-		
Crystalloids	3107 [2760–3454]	3516 [3009-4024]	0.17
Colloids	268 [126–409]	358 [175–540]	0.43
Blood products	8 [-8-25]	44 [-45-133]	0.41





Table 2. Fluids Administered, Blood Loss, Hemodynamic Status, Physiologic Status, and Renal Function During and After Surgery in the Pleth Variability Index (PVI) Group (PVI-Guided Fluid Management) and in the Control Group

Lactate levels (mMol⋅L ⁻¹)	PVI group (<i>N</i> = 41)	Control group $(N = 41)$	<i>P</i> value
Maximum intraoperative	1.2 [1–1.4]	1.6 [1.2–2]	0.04
At 24 hours	1.4 [1.3–1.5]	1.8 [1.5–2.1]	0.02
At 48 hours	1.2 [1–1.3]	1.4 [1.2–1.5]	0.03
Lactate levels >1.7 mMol·L ⁻¹			
Intraoperatively	7 (17)	4 (10)	0.33
At 24 hours	2 (5)	28 (68)	< 0.0001
At 48 hours	0	8 (20)	0.003
Lactate levels >5 mMol·L ⁻¹			
Intraoperatively	0	1 (2)	0.31
At 24 hours	0	1 (2)	0.31
At 48 hours	0	1 (2)	0.31
Intraoperative hypotension	22 (54)	28 (68)	0.17






Table 2. Fluids Administered, Blood Loss, Hemodynamic Status, Physiologic Status, and Renal Function During and After Surgery in the Pleth Variability Index (PVI) Group (PVI-Guided Fluid Management) and in the Control Group

	PVI group	Control group	
	(N=41)	(N=41)	P value
Intraoperative hypotension	22 (54)	28 (68)	0.17
Continuous infusion of norepinephrine			
Intraoperative	9 (22)	9 (22)	1.0
At 24 hours	3 (7)	1 (2)	0.31
Renal function diuresis			
Intraoperative oliguria	13 (32)	17 (42)	0.34
Postoperative oliguria (24 hours)	3 (8)	3 (8)	0.97
Serum creatinine (mg · dL ⁻¹)			
At 24 hours	1.01 [0.9–1.1]	1.12 [0.9–1.3]	0.32
At 48 hours	0.91 [0.8–1]	1.09 [0.9–1.3]	0.11
Initiation of dialysis	1 (2)	0 (0)	0.32





Forget P, Lois F and De Kock M, Anesth Analg 2010.



Table 3. Postoperative Complications and Intensive Care Unit/Hospital Stay in the Pleth Variability Index (PVI) Group (PVI-Guided Fluid Management) and in the Control Group

	PVI group (<i>N</i> = 41)	Control group (N = 41)	<i>P</i> Value
Postoperative complications			
Infection of surgery site	8 (20)	8 (20)	1.0
Other infections (pulmonary, line-related, other abdominal)	6 (15)	7 (17)	0.77
Cardiovascular complications (acute myocardial infarction,	4 (10)	8 (20)	0.26
acute lung injury/acute respiratory distress			
syndrome, pulmonary edema, arrhythmia)			
Coagulopathy	5 (12)	6 (15)	0.75
Nausea and/or vomiting	O (O)	4 (16)	0.08
Upper digestive hemorrhage	4 (10)	3 (7)	0.78
Leakage of anastomosis	5 (12)	5 (12)	1.0
Morbidity (event per patient)	1.2 ± 1.8	1.5 ± 2.2	0.46
Mortality	2 (5)	O (O)	0.16
Length of stay			
Postoperative mechanical ventilation	1 (2)	3 (7)	0.31
Intensive care unit (days)	2.2 ± 5.7	1.8 ± 7.2	0.71
Hospital (days)	15.1 ± 14.3	16.0 ± 17.8	0.78

Forget P, Lois F and De Kock M, Anesth Analg 2010.





- Tailored fluid administration is associated with improved morbidity and hospital length of stay
- Focusing on optimization of CO help in the choice of monitoring methods
- More studies are needed to confirm the clinical value and the limits of available fluid responsiveness monitoring methods



Conclusion (2)



- The PVI allows for noninvasive, automated, continuous of fluid responsiveness monitoring
- Our study add evidence to the concept of Goal-Directed fluid management